Skip to content

Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention

Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04236596
Enrollment
22
Registered
2020-01-22
Start date
2020-09-14
Completion date
2023-06-08
Last updated
2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Underactive Bladder, Urinary Retention

Keywords

pudendal nerve mapping

Brief summary

This study is to map the pudendal nerve. In this study the researchers will examine subjects who are already receiving an implanted stimulator at their pudendal nerve as part of their normal clinical care.

Detailed description

The pudendal nerve goes to the urethra, anus, and other areas of the pelvic floor. Electrical stimulation of this nerve can help with bladder problems and pelvic pain. Researchers do not understand how the nerve anatomy is different between people. Successfully mapping the pudendal nerve may help improve the medical care for future patients with bladder problems, pelvic pain, bowel problems, and sexual problems.

Interventions

DEVICEParticipants received a Neurostimulator, which was used to map the pudendal nerve

Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
University of Michigan
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinically referred as having bladder problems that have not responded to conservative treatment. Normal clinical care includes referral to implant of Medtronic Interstim neurostimulator at the pudendal nerve. Fully eligible to receive an Interstim implant. * Adult (18 or older), capable of providing own informed consent and communicating clearly with research team * Capable of speaking, reading, and understanding English, as all study questionnaires are standardized assessments only available in English * Capable of attending all experimental sessions (Visit 1: pre-stage-1 imaging, Visit 2: stage-1 surgery, Visit 3: CT after stage-2 surgery, Visit 3: cystometrogram test) Exclusion * Implanted materials that prohibit magnetic imaging * Any medical problems that prevent an individual from laying flat in an MRI or CT scanner, are are claustrophobic. * Areflexive or atonic bladder * Pregnant or planning to become pregnant. If a woman of child-bearing potential wishes to participate in this study, they will be pre-screened with a test to detect pregnancy. * Diagnosed neurogenic bladder, pudendal nerve damage, lower motor dysfunction, or other conditions that would affect the neural circuits involved in micturition. * Unwilling to allow de-identified data to be stored for future use or shared with other researchers.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Evoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During the Stage-4 TestVisit 4, approximately 10 weeks after consentThe primary outcome measure in this study was an evoked bladder contraction of at least 20 centimeters of water (cmH2O) during the cystometrogram. These bladder contractions were evoked by applying nerve stimulation to the pudendal nerve through testing of the participant's implanted stimulator. Measure reflects number of participants who experienced an evoked bladder contraction of at least 20 centimeters of water during nerve stimulation.

Secondary

MeasureTime frameDescription
Selectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Participant StimulationVisit 2: Stage-1 (approximately 3 weeks after consent)Selectivity refers to the degree in which a nerve could be stimulated without stimulating other nerves. SI was calculated for each sensor recording from locations innervated by distal pudendal nerve branches during the visit-2 implant procedure. This includes pressure sensors in the urethra innervated by the perineal nerve and anal electromyography (EMG) innervated by the ischeal rectal nerve. The SI calculation used here is on a scale of 0 to 1, with 0 indicating no response at all from the nerve. The closer the number is to 1, the more selective the nerve stimulated.
Selectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Simulated Model StimulationApproximately one year and four months after consentSelectivity is the degree to which part of a nerve could be stimulated without stimulating other nerve parts. For each participant who had successful MRI and CT images, a computational model was created to simulate electrical stimulation of axons distributed in two primary pudendal fascicles: perineal and rectal. The SI of stimulation does not indicate a positive or negative result in this outcome; rather, it shows the relative potential for activating just a single nerve fascicle. The negative/positive designation identifies the regional nerve activation, with -1 representing only perineal fascicle activation, +1 representing only rectal activation, and 0 indicating equal activation of both fascicles.
Measurement of Effect of Pudendal Nerve Stimulation on Urethral Leak Point Pressure During the Stage-4 TestVisit 4, approximately 10 weeks after consentA secondary outcome measure was a goal to examine the effect of selective pudendal nerve stimulation on urethral leak point pressure during the cystometrogram.

Countries

United States

Participant flow

Participants by arm

ArmCount
Study Participants
Study participants received an implanted neurostimulator at their pudendal nerve and consented to participate in study activities.
22
Total22

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyParticipants did not receive implant at all4
Overall StudyParticipants did not retain implant for entire trial3
Overall StudyWithdrawal by Subject1

Baseline characteristics

CharacteristicStudy Participants
Age, Continuous54.37 years
STANDARD_DEVIATION 13.15
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
21 Participants
Region of Enrollment
United States
22 Participants
Sex: Female, Male
Female
18 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 22
other
Total, other adverse events
0 / 22
serious
Total, serious adverse events
0 / 22

Outcome results

Primary

Number of Participants With Evoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During the Stage-4 Test

The primary outcome measure in this study was an evoked bladder contraction of at least 20 centimeters of water (cmH2O) during the cystometrogram. These bladder contractions were evoked by applying nerve stimulation to the pudendal nerve through testing of the participant's implanted stimulator. Measure reflects number of participants who experienced an evoked bladder contraction of at least 20 centimeters of water during nerve stimulation.

Time frame: Visit 4, approximately 10 weeks after consent

Population: Due to scheduling conflicts and participant attrition, only 10 participants completed this part of the study. All were women.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Participants Undergoing CystometrogramNumber of Participants With Evoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During the Stage-4 Test0 Participants
Secondary

Measurement of Effect of Pudendal Nerve Stimulation on Urethral Leak Point Pressure During the Stage-4 Test

A secondary outcome measure was a goal to examine the effect of selective pudendal nerve stimulation on urethral leak point pressure during the cystometrogram.

Time frame: Visit 4, approximately 10 weeks after consent

Population: Selective pudendal nerve stimulation was not performed during the cystometrogram sessions due to time limitations within experimental sessions, so there is no data available. Selectivity could not be accomplished as it was described in the protocol for this nerve bundle.

Secondary

Selectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Participant Stimulation

Selectivity refers to the degree in which a nerve could be stimulated without stimulating other nerves. SI was calculated for each sensor recording from locations innervated by distal pudendal nerve branches during the visit-2 implant procedure. This includes pressure sensors in the urethra innervated by the perineal nerve and anal electromyography (EMG) innervated by the ischeal rectal nerve. The SI calculation used here is on a scale of 0 to 1, with 0 indicating no response at all from the nerve. The closer the number is to 1, the more selective the nerve stimulated.

Time frame: Visit 2: Stage-1 (approximately 3 weeks after consent)

Population: Data was collected from 16 participants who received the implant.

ArmMeasureGroupValue (MEAN)Dispersion
Participants Undergoing CystometrogramSelectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Participant StimulationPerineal nerve0.57 indexStandard Deviation 0.29
Participants Undergoing CystometrogramSelectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Participant StimulationRectal nerve0.90 indexStandard Deviation 0.22
Secondary

Selectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Simulated Model Stimulation

Selectivity is the degree to which part of a nerve could be stimulated without stimulating other nerve parts. For each participant who had successful MRI and CT images, a computational model was created to simulate electrical stimulation of axons distributed in two primary pudendal fascicles: perineal and rectal. The SI of stimulation does not indicate a positive or negative result in this outcome; rather, it shows the relative potential for activating just a single nerve fascicle. The negative/positive designation identifies the regional nerve activation, with -1 representing only perineal fascicle activation, +1 representing only rectal activation, and 0 indicating equal activation of both fascicles.

Time frame: Approximately one year and four months after consent

Population: Computational models were created for 10 participants who received the implant. The model data was segregated into three groups: participants with selectivity indices positive (\>0) for all four contacts (rectal only), negative (\<0) for all four contacts (perineal only), and mixed (both \>0 and \<0). Each group has the same potential range for SI values: -1 to +1. Values in the Outcome Measure Data Table are calculations across all lead contacts and participants per group.

ArmMeasureGroupValue (MEAN)Dispersion
Participants Undergoing CystometrogramSelectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Simulated Model StimulationRectal dominant0.577 indexStandard Deviation 0.193
Participants Undergoing CystometrogramSelectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Simulated Model StimulationPerineal dominant-0.533 indexStandard Deviation 0.284
Participants Undergoing CystometrogramSelectivity Index (SI) for Selective Stimulation of Pudendal Nerve Branches for Simulated Model StimulationMixed0.288 indexStandard Deviation 0.666

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026